Scholarlink

<p>G-protein-coupled receptors (GPCRs) transmit cellular signals through both G protein and arrestin pathways and biased signaling offers potential therapeutic advantages through selective activation. Although GPCR–G protein complexes are well characterized, structural understanding of class B GPCR–arrestin interactions remains limited. Here we show the cryo-electron microscopy structure of parathyroid hormone receptor 1 in core engagement with β-arrestin 1, revealing the molecular basis of arrestin coupling. The structure shows a rearrangement in which inward movement of extracellular transmembrane helix 5 (TM5) and extracellular loop 3 (ECL3) drives outward displacement of cytoplasmic TM5, forming a configuration required for arrestin binding. Guided by comparison with the G<sub>s</sub>-coupled state, we designed peptide analogs that prevent these TM5/ECL3 conformational changes, producing G-protein-biased agonists that preserve agonist efficacy while reducing arrestin recruitment. In an ovariectomized mouse model, a lead compound shows comparable therapeutic efficacy, providing a framework for structure-guided design of biased therapeutics targeting class B GPCRs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structural basis of PTH1R–β-arrestin core engagement reveals design principles for G-protein-biased therapeutics

  • 期刊论文

  • 发表日期：

    2026年5月11日

查看全文
  • Li-Hua Zhao,
  • Qian He,
  • Qingning Yuan,
  • Min Zhang,
  • Guan-Guan Zhao,
  • Jie Sun,
  • Wen Hu,
  • Hong Shan,
  • H. Eric Xu

摘要

G-protein-coupled receptors (GPCRs) transmit cellular signals through both G protein and arrestin pathways and biased signaling offers potential therapeutic advantages through selective activation. Although GPCR–G protein complexes are well characterized, structural understanding of class B GPCR–arrestin interactions remains limited. Here we show the cryo-electron microscopy structure of parathyroid hormone receptor 1 in core engagement with β-arrestin 1, revealing the molecular basis of arrestin coupling. The structure shows a rearrangement in which inward movement of extracellular transmembrane helix 5 (TM5) and extracellular loop 3 (ECL3) drives outward displacement of cytoplasmic TM5, forming a configuration required for arrestin binding. Guided by comparison with the Gs-coupled state, we designed peptide analogs that prevent these TM5/ECL3 conformational changes, producing G-protein-biased agonists that preserve agonist efficacy while reducing arrestin recruitment. In an ovariectomized mouse model, a lead compound shows comparable therapeutic efficacy, providing a framework for structure-guided design of biased therapeutics targeting class B GPCRs.